Ignitis Group reports increased green capacity installations and financial growth for full-year 2025

Darius Maikštėnas CEO
Darius Maikštėnas CEO
0Comments

AB “Ignitis grupė” (Ignitis Group), an integrated utility with a focus on renewables, reported its financial and operational results for 2025. The company’s adjusted EBITDA reached 546.1 million euros, representing a 3.4% increase from the previous year and surpassing the upper end of its full-year guidance range of 510–540 million euros. The growth was attributed mainly to strong performance in its Green Capacities and Networks segments.

Total investments amounted to 720.3 million euros, which fell within the company’s guidance range of 700–800 million euros. Of this amount, 53.1% was allocated to Networks and 39.7% to Green Capacities, focusing primarily on new solar and onshore wind projects.

The company increased its installed green capacities by 0.7 gigawatts (GW), rising from 1.4 GW to 2.1 GW over the year as six wind and solar farm projects reached commercial operation dates in Lithuania, Latvia, and Poland. Among these were the Kelmė wind farm in Lithuania (313.7 MW), Silesia wind farm II in Poland (136.8 MW), and a cluster of solar farms in Latvia totaling more than 239 MW.

Final investment decisions were also made for battery energy storage systems at three sites in Lithuania: Kelmė (147.4 MW), Kruonis (99.2 MW), and Mažeikiai (45.1 MW).

In the Networks segment, Ignitis Group continued modernizing its distribution infrastructure and updated its ten-year investment plan for distribution networks covering 2024–2033, aligning it with regulatory authorities in January 2025. The revised plan foresees a total investment of 3.5 billion euros—40% higher than the previous decade’s plan.

The group completed a mass roll-out of smart meters, installing a total of 1.3 million units across its service area.

In other activities, Ignitis Group secured contracts through Polish capacity mechanism auctions to ensure electricity capacity availability in upcoming years and expanded its electric vehicle charging network by adding more than 700 charging points during the year.

On sustainability metrics, Ignitis Group reported that renewable sources accounted for over 70% of generation output while carbon intensity stood at 248 grams CO2-equivalent per kilowatt-hour for Scope 1 and Scope 2 emissions; no fatalities occurred during operations in the reporting period.

S&P Global Ratings reaffirmed Ignitis Group’s credit rating at ‘BBB+’ with a stable outlook following their September review.

Darius Maikštėnas, CEO of Ignitis Group, stated: “With record strategic progress, Ignitis Group has reinforced its position as a leading force in the Baltic energy transition. Our targeted investments across Lithuania, Latvia, Estonia and Poland strengthen regional energy security and build an energy abundant ecosystem, leading to globally competitive prices for consumers, and sustainable economic growth.”

For shareholders, Ignitis Group proposed dividends totaling EUR 1.366 per share for the year—a rise of three percent compared to last year—amounting to nearly EUR 98.9 million overall.

Looking ahead to next year, Ignitis Group expects adjusted EBITDA between EUR 550–600 million with planned investments ranging from EUR 590–690 million.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.